Lilly and AstraZeneca have entered a clinical trial collaboration to evaluate the safety and efficacy of AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with CYRAMZA (ramucirumab), Lilly’s VEGF Receptor 2 antiangiogenic cancer drug, in patients with advanced solid tumors. The Phase I study is expected to establish a dosing regimen. The trial will be sponsored by Lilly. Additional details and financial terms were not disclosed. MEDI4736...